KLRC1 and neoplasm: Having established that numerous tumor types upregulate HLA‐E/Qa‐1b levels as a mechanism to resist the killing of NK and T cells, NKG2A checkpoint inhibitors have been developed and demonstrated to unleash their cytotoxic activity against tumors in both preclinical and clinical investigations.11